The Valley Desk

Clinical trial reportLancet (London, England)Published

First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial

Read the publication ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Jefferson Health. Affiliation source

Institution
Jefferson Health

Publication record

Type
Clinical trial report
Venue
Lancet (London, England)
Published
Subject terms
Humans; Endometrial Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Carboplatin; Antineoplastic Combined Chemotherapy Protocols; Quality of Life; Aged; Middle Aged; Female; Antibodies, Monoclonal, Humanized
PubMed ID
42933458
Added to directory
Source checked

Report a correction or request removal